Indian startups plan affordable CAR-T therapies—first for domestic use, then for the global market.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Signal Transduction and Targeted Therapy Open Access 19 September 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jayaraman, K. Cut-price CAR-T cell therapies top India’s biotech agenda. Nat Biotechnol 37, 1388–1389 (2019). https://doi.org/10.1038/s41587-019-0346-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-019-0346-1
This article is cited by
-
Equitable access to cell and gene therapies in South Africa: opportunities and hurdles
Gene Therapy (2023)
-
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Signal Transduction and Targeted Therapy (2022)